Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data

Boehringer Ingelheim and Zealand Pharma on Friday unveiled Phase II findings for their investigational GLP-1/glucagon receptor dual agonist survodutide, which significantly improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis.